If you have been told there is no science behind MCS, that is not true — and this page is the proof. Below are the peer-reviewed studies in our library, published in indexed medical and scientific journals over more than thirty years, by researchers in more than fifteen countries. They document what happens in the body: nerve receptors that become over-reactive, immune cells that release inflammatory chemicals at trace exposures, inherited differences in how bodies clear chemicals, changes visible on brain imaging, and symptoms that measurably improve when the air is cleaned up.
You do not have to take our word for any of it. Every entry links straight to the original journal source, so you — or your doctor — can read it directly. That is the point of this page: when someone tells you this is not real, you should not have to argue from your own experience alone. You should be able to hand them the literature. Use the filters below to browse by topic, or scroll the full collection.
One honest note about what this research does not yet do. It has not settled on a single agreed cause, and there are no large controlled treatment trials. Researchers still disagree about mechanisms. But the disagreement is about why this happens to people — not whether it does.
Molot J, Sears M, Anisman H — Neurosci Biobehav Rev, 2023
2023 narrative review arguing that MCS is a biological condition involving TRPV1/TRPA1 receptor sensitization, affecting an estimated 13–26% of Americans.
View Source →Allen JG et al. — Environ Health Perspect, 2016
Harvard-led controlled study showing indoor VOC exposure reduces cognitive scores by 61%; green building conditions dramatically improve mental performance.
View Source →Steinemann A — J Occup Environ Med, 2018
12.8% of Americans have diagnosed MCS—a 300% increase in a decade—with 86% reacting to fragranced products.
View Source →Perales RB et al. — Prim Health Care Res Dev, 2022
Small demonstration correlating measured indoor VOC reductions with symptom improvement in CI patients through environmental house calls.
View Source →Zhu J, Wong SL, Cakmak S — Environ Sci Technol, 2013
Health Canada survey detecting close to 50 different VOCs in more than half of 3,857 homes; apartments consistently showed higher concentrations than houses.
View Source →Dodson RE et al. — J Expo Sci Environ Epidemiol, 2021
Women use a median of 8 personal care products daily, with women of color facing higher chemical burdens from products marketed specifically to them.
View Source →Driesen L, Patton R, John M — J Psychosom Res, 2020
Systematic review of studies reporting that MCS limits social participation, employment, and healthcare access; stigma from disbelief compounds disability.
View Source →Braithwaite I et al. — Environ Health Perspect, 2019
Meta-analysis of 22 studies finding PM2.5 exposure associated with approximately 10% increased depression risk and elevated suicide rates.
View Source →Dantoft TM et al. — Curr Rheumatol Rev, 2015
Comprehensive review of CI epidemiology, clinical features, and proposed mechanisms finding 9–16% global self-reported prevalence across multiple countries.
View Source →Molot J et al. — Rev Environ Health, 2022
MCS and neurodegenerative diseases share overlapping TRPV1/TRPA1 pathways; genetic receptor polymorphisms may determine which trajectory follows chemical exposure.
View Source →Lacour M et al. — Int J Hyg Environ Health, 2005
Proposes CNS involvement should be explicitly required in MCS case definitions, as cognitive symptoms are virtually universal and most diagnostically specific.
View Source →Gibson PR, Elms AN, Ruding LA — Environ Health Perspect, 2003
Patient survey finding chemical avoidance and safe living environments rated far more helpful than any medical treatment; psychotropic medications rated least helpful.
View Source →Potera C — Environ Health Perspect, 2011
The top 25 best-selling scented consumer products each emit an average of 17 VOCs, including hazardous air pollutants not disclosed on product labels.
View Source →Johnson D, Colman I — J Psychosom Res, 2017
Canadian survey showing MCS is associated with markedly elevated mood disorders; the cross-sectional design cannot settle direction; the authors discuss both.
View Source →Rossi S, Pitidis A — J Occup Environ Med, 2018
Review finding the 1999 consensus criteria remain the most accepted MCS definitions; prevalence 0.5–3.9% diagnosed, 10–20% self-reported.
View Source →Leech JA et al. — J Expo Anal Environ Epidemiol, 2002
Time-activity study finding that people spend approximately 87% of their time in indoor environments, making IAQ the primary determinant of chemical exposure.
View Source →Cohen AJ et al. — Lancet, 2017
Global Burden of Disease analysis attributing 4.2 million deaths annually to ambient air pollution through the same oxidative stress and inflammatory mechanisms central to MCS.
View Source →Orriols R et al. — J Neurol Sci, 2009
Spanish SPECT study reporting measurable SPECT differences in MCS patients to chemical exposures than healthy controls.
View Source →McKeown-Eyssen GE et al. — Arch Environ Health, 2001
Case-definition study finding the 1999 six-criteria MCS definition discriminates patients from controls and related conditions.
View Source →Skovbjerg S et al. — Scand J Public Health, 2009
Danish qualitative study in which participants rated chemical avoidance the most helpful strategy; psychotropic medications consistently rated least helpful.
View Source →Andersson L et al. — Int J Hyg Environ Health, 2017
MCS sensitizers show lower pain-inhibiting rACC activation and elevated insula activity, placing MCS mechanistically within central sensitization syndromes.
View Source →Andersson L et al. — Iperception, 2020
Signal detection theory reveals chemical intolerance involves a lowered neurological decision threshold—a response-bias effect the authors distinguish from greater sensory sensitivity.
View Source →Katerndahl DA et al. — Ann Fam Med, 2012
20.3% of 400 primary care patients met CI criteria, yet the condition is rarely diagnosed despite causing significantly poorer functional status and elevated healthcare use.
View Source →Masri S et al. — Environmental Sciences Europe, 2021
Analysis of survey data finding VOCs, pesticides, and combustion products most consistently associated with triggering toxicant-induced loss of tolerance across eight major real-world exposure events.
View Source →Marshall L et al. — CMAJ, 2002
Introduces the CH2OPD2 mnemonic for systematic environmental exposure history-taking—a clinically essential but systematically neglected skill.
View Source →Millqvist E — Allergy, 2000
Reports capsaicin inhalation challenge as a safe, dose-dependent objective test for TRPV1 receptor hypersensitivity in chemically sensitive patients.
Hillert L et al. — Hum Brain Mapp, 2007
PET study of MCS (n=12) showing increased ACC and precuneus activation with decreased olfactory processing during chemical odorant exposure.
View Source →Caress SM, Steinemann AC — J Occup Environ Med, 2005
National population study: asthma and chemical hypersensitivity co-occur in approximately 40% of cases, an association the authors note without establishing a shared mechanism.
View Source →Li Y, Cakmak S, Zhu J — Environ Int, 2019
National Canadian survey of 3,524 homes finding limonene, silicones, and toluene among highest-concentration VOCs; apartments consistently worse than houses.
View Source →Lipson JG — Med Anthropol Q, 2004
Medical anthropology study: systematic disbelief from physicians, employers, and family compounds MCS disability and provides cultural license for discrimination.
View Source →Nordin S et al. — Int Arch Occup Environ Health, 2004
CSS development showing direct correlation with capsaicin cough sensitivity, consistent with the scale tracking airway sensory hyperreactivity.
View Source →Vuokko A et al. — Int J Environ Res Public Health, 2018
Documents severe functional disability from environmental intolerance even within one of the world\'s more supportive legal and clinical frameworks.
View Source →Graveling RA et al. — Occup Environ Med, 1999
Balanced review concluding neurobiological sensitization—particularly in limbic and olfactory systems—provides the most coherent mechanistic account of MCS.
View Source →Azuma K et al. — PLoS One, 2013
Japanese NIRS imaging showing MCS patients have abnormal bilateral prefrontal cortex blood flow during chemical odor stimulation, with progressive failure to distinguish odors.
View Source →Azuma K et al. — Environ Health Prev Med, 2015
MCS patients show sustained orbitofrontal cortex activation persisting 20–30 seconds after odor exposure ends, consistent with prolonged clinical symptom duration.
View Source →Azuma K et al. — PLoS One, 2016
MCS patients detect the same chemical concentration as controls but show dramatically greater and more prolonged brain activation—objective neurological evidence.
View Source →Khan A et al. — PLoS Biol, 2019
Study of 151 million Americans and 1.4 million Danes: poor air quality associated with up to 162% increase in personality disorder rates and 50% increase in depression.
View Source →Johansson A et al. — Chest, 2006
Population-based study formally defining airway sensory hyperreactivity (SHR) at 6.3% prevalence—comparable to asthma—and validating patient self-report against objective receptor testing.
View Source →Holst H et al. — Int J Hyg Environ Health, 2010
Danish study finding MCS patients with respiratory symptoms show elevated capsaicin cough sensitivity not explainable by asthma alone.
View Source →Holst H et al. — Clin J Pain, 2011
MCS patients have significantly larger zones of secondary hyperalgesia, demonstrating CNS-level sensitization beyond peripheral receptor effects.
View Source →Kimata H — Int J Hyg Environ Health, 2004
Elevated baseline NGF in MCS patients\' nasal secretions is reported after VOC exposure; a candidate mechanism for sustained sensitization, not a demonstrated one.
View Source →Dantoft TM et al. — PLoS One, 2021
Danish general-population cohort in which MCS co-occurs substantially with ME/CFS and fibromyalgia; shared central sensitization is the authors’ interpretation, not a finding.
View Source →Gibson PR, Vogel VM — J Clin Nurs, 2009
Survey of 305 MCS patients: disability magnitude is comparable to major chronic conditions; two-thirds of the most severely affected had left or been forced from their jobs.
View Source →Kreutzer R, Neutra RR, Lashuay N — Am J Epidemiol, 1999
Early California survey (not national) finding 15.9% of respondents reported chemical sensitivity——with women disproportionately affected.
View Source →Lipson JG — Qual Health Res, 2001
Ethnographic study: MCS patients develop labor-intensive self-care strategies in the absence of medical support; chemical avoidance emerges as the most consistently validated approach.
View Source →Millqvist E — Temperature (Austin), 2015
Clinical review proposing TRPV1 and TRPA1 as the mechanistic basis for sensory airway hyperreactivity and suggesting why conventional asthma treatments fail for chemically sensitive patients.
View Source →Chiaravalloti A et al. — Eur J Nucl Med Mol Imaging, 2015
Italian FDG-PET study: MCS patients show frontal deactivation and limbic overactivation during olfactory stimulation—an objective difference in this cohort.
View Source →Silva-Néto RP, Peres MF, Valença MM — Cephalalgia, 2014
Study of 400 headache patients: odor-triggered headaches in 70% of migraineurs vs. 0% with tension-type; perfume, paints, gasoline, and bleach as leading triggers.
View Source →Andersson L et al. — J Psychosom Res, 2014
IEI/MCS patients show altered brain activation to both olfactory and trigeminal chemical stimuli, demonstrating abnormal chemosensory processing across the full trigeminal system.
View Source →Azuma K et al. — Environ Health Prev Med, 2019
Comprehensive review synthesizing all published neuroimaging studies (PET, SPECT, NIRS, fMRI): consistently finding altered prefrontal, cingulate, and limbic activation.
View Source →Millqvist E, Ternesten-Hasséus E, Bende M — Pulm Pharmacol Ther, 2008
Inhaled ethanol potentiated the capsaicin cough response in patients with airway sensory hyperreactivity, which may explain why “unscented” products with alcohol-based preservatives can still trigger MCS reactions.
View Source →Millqvist E, Löwhagen O, Bende M — Allergy, 2000
Capsaicin sensitivity correlated with quality-of-life impairment in this cohort, supporting capsaicin challenge as a clinically meaningful marker.
View Source →Del Casale A et al. — Int J Environ Res Public Health, 2020
Principal component analysis of 218 MCS patients: neurological/cognitive symptoms (brain fog, headache, dizziness) are the most universal feature and most disabling occupationally.
View Source →Lax MB, Henneberger PK — Arch Environ Health, 1995
Early clinical series: MCS patients who reduced chemical exposures through job change or relocation improved; those managed with reassurance and psychiatric referral did not.
View Source →Anonymous (34 North American Clinicians) — Arch Environ Health, 1999
Consensus statement by 34 clinicians setting out the six criteria that most later research uses to define MCS.
View Source →Schnakenberg E et al. — Environ Health, 2007
Slower or absent detoxification enzyme variants (NAT2 slow acetylators, GSTM1 and GSTT1 deletions) were significantly more common in people who reported chemical sensitivity, consistent with a biological susceptibility; later studies have not consistently confirmed them.
View Source →Sandoval-Diez N et al. — Environ Int, 2026
18-year nationwide Swiss cohort of 3.5 million adults found long-term residential ELF magnetic field exposure from high-voltage power lines associated with increased Alzheimer’s disease and dementia mortality. Associations began at 0.5 milligauss and were strongest in the 1–3 mG range — levels commonly found in homes near power line infrastructure.
View Source →Laván D et al. — Front Neurol, 2025
Systematic review finding that exposure to 2.4 GHz Wi-Fi radiation can alter expression of genes involved in DNA repair and metabolism, and induce oxidative stress responses in neural tissue. Authors conclude evidence reinforces the possibility of adverse cellular and genetic health effects from prolonged RF-EMF exposure; causal link not yet reported and further research is needed.
View Source →McKeown-Eyssen G et al. — Int J Epidemiol, 2004
Case-control study of 203 MCS cases and 162 controls found significantly higher odds of MCS in women with fast (extensive) CYP2D6 metabolism and fast-acetylating NAT2 genotypes, compared to the slow forms of each enzyme. Women with the fast form of both genes had roughly 18-fold higher odds of chemical intolerance than those with the slow form of both. Proposed mechanism: fast Phase 1 metabolism generates reactive intermediate byproducts faster than Phase 2 enzymes can neutralize them.
View Source →Schnakenberg E et al. — Environ Health, 2007
Cross-sectional study of 521 individuals found significant differences in NAT2, GSTM1, and GSTT1 gene variant distribution between people with self-reported chemical sensitivity and those without. GSTM1-null and GSTT1-null genotypes (complete deletion of these Phase 2 detoxification enzymes) were significantly more common in the chemically sensitive group.
View Source →Alcorta E, Gomez-Diaz C — Int J Mol Sci, 2025
Whole-exome sequencing case-control study (6 MCS patients, 5 controls) found a statistically significant excess of rare homozygous variants in the SLC transporter gene superfamily among MCS patients (p < 0.01), with each patient carrying at least one such variant. By contrast, for CYP2D6 specifically, more rare variants appeared in the control group than the patient group -- the opposite of what would be expected if CYP2D6 were an MCS susceptibility gene. Very small sample; authors describe results as hypothesis-generating, not confirmatory.
View Source →Sajewski ET et al. — MMWR Surveill Summ, 2026
Five years of active, laboratory-based CDC surveillance through the Georgia Emerging Infections Program at three laboratories serving four Atlanta hospitals (two academic plus outpatient clinics, one federal, one community). Of 968 patients flagged by positive mold culture or Aspergillus galactomannan, 449 met invasive mold disease surveillance definitions — 89 proven, 142 probable, 218 broader surveillance. 68% pulmonary, 71% Aspergillus, 50% mechanically ventilated, 30% died in hospital, 45% 90-day ALL-CAUSE mortality. Nearly all patients were immunocompromised or critically ill. Finds that this rare, severe disease is undercounted because it is not nationally notifiable and is hard to diagnose. Does NOT study household mold exposure, MCS, CIRS, or chronic water-damaged-building illness, and does not determine where any patient encountered the responsible mold.
View Source →Miller CS et al. — Environmental Sciences Europe, 2021
Study proposing mast cell activation as the unifying biological mechanism for chemical intolerance: 59% of MCAS patients met criteria for CI, with symptom and intolerance patterns nearly identical between the two groups.
View Source →Heilbrun LP et al. — J Am Board Fam Med, 2015
Case-control study of 694 mothers finding that those with children diagnosed with autism or ADHD had significantly higher chemical intolerance scores and more drug reactions than controls. Observational — association, not found causation.
View Source →Palmer RF et al. — J Xenobiot, 2024
Replication of the 2015 finding: comparing the highest to the lowest decile of parental chemical-intolerance scores gave a risk ratio of 5.7 for autism and 2.1–2.8 for ADHD. Proposes epigenetic mast-cell changes as the mechanism; observational, so causality is not found.
View Source →Miller CS — Addiction, 2001
Theoretical paper arguing addiction and chemical intolerance are opposite expressions of one underlying breakdown in innate tolerance — addicts seek exposures and the chemically intolerant avoid them, both to escape withdrawal symptoms.
View Source →Kucharik AH, Chang C — Clin Rev Allergy Immunol, 2020
The most-cited review of the hEDS/POTS/MCAS overlap. Proposes bidirectional fibroblast–mast cell interaction in connective tissue as a candidate shared mechanism; explicitly notes diagnostic criteria across all three conditions are still inconsistent.
View Source →Valdez JA et al. — J Allergy Clin Immunol Pract, 2026
Mayo Clinic study reporting a lack of evidence for increased mast cell activation syndrome prevalence in people with POTS, hEDS, or both. Kept on this site as the contrary evidence to the widely shared overlap claim. NOTE: online ahead of print with no abstract published as of 16 Sep 2026 — this summary states the paper’s title finding only; population, design and numbers are not yet public.
View Source →Joo T et al. — Environ Sci Technol Lett, 2021
A commercial hydroxyl radical generator run in an ordinary office produced enhancements in oxygenated VOCs — especially low-molecular-weight organic acids — followed by rapid increases in airborne particle number and mass, corresponding to highly oxidised secondary organic aerosol. Included because it documents the mechanism by which an air-cleaning device can generate ultrafine particulate and secondary irritants in occupied space rather than only removing pollutants. The device tested was unnamed and is not any specific brand sold to this audience.
View Source →Hauge CR et al. — J Psychosom Res, 2015
The one randomized controlled trial in diagnosed MCS (n=69). MBCT improved illness perception and did not improve overall MCS illness status, anxiety or depression at one year. Contrary evidence for mind-body approaches as treatment of the illness; leads this category for that reason.
View Source →Skovbjerg S et al. — Scand J Psychol, 2012
Randomized pilot (n=37) preceding the 2015 trial. No between-group effect. Read together with Hauge 2015: the controlled evidence in MCS does not show mind-body therapy changing the illness.
View Source →Das-Munshi J, Rubin GJ, Wessely S — J Allergy Clin Immunol, 2006
The strongest evidence for a psychological explanation, kept on this site deliberately: 37 provocation studies, 784 people with MCS and 547 controls. Masked-odor studies were null — and people with MCS reacted more than controls to both chemical and sham. Blinding was inadequate in most studies; every subject already had MCS, so the review says nothing about onset.
View Source →Goudsmit EM, Howes S — Journal of Nutritional & Environmental Medicine, 2008
Reanalysis of the provocation literature: two of the three cleanest negative studies selected subjects by self-reported belief rather than diagnosis, and the psychological case was overstated. The methodological counterpart to Das-Munshi 2006.
View Source →Baines CJ et al. — Occup Med (Lond), 2004
Companion laboratory paper to the Toronto genotype study: 223 cases and 194 controls, routine biochemistry unremarkable. The often-quoted 223/194 figures belong to this paper, not to the genetics paper (203 women, 162 controls).
View Source →Bosch-Capblanch X et al. — Environ Int, 2024
41 studies, 2,874 participants: no symptom effect from radiofrequency exposure below regulatory limits. Contrary evidence on EMF as the trigger of EHS symptoms, and this site treats it as such; the design limits of short single-source provocation keep the question open without turning a null into a positive.
View Source →Azuma K, Uchiyama I, Kunugita N — J Psychosom Res, 2019
Population cohort of more than seven thousand adults followed five years, in a broader and milder self-reported group than consensus MCS. Intolerance both improved and developed; improvement was linked to regular physical activity and lifestyle rather than environmental change, onset to atopic dermatitis and negative psychosomatic states. Weighed on this site as contrary evidence.
View Source →Black DW, Okiishi C, Schlosser S — Psychosomatics, 2000
Small Iowa cohort, eighteen people re-interviewed after nine years: improved, but most still symptomatic. One of the few long-term natural-history records of MCS — chronic with fluctuation, managed rather than cured.
View Source →Hempel S et al. — BMJ Open, 2025
A protocol for what would be the first full accounting: an evidence map of more than 350 studies and dozens of proposed markers with no accepted biomarker. The systematic review that follows is the one this site has committed to report straight, whichever way it lands.
View Source →MCS affects an estimated 3–16% of the general population depending on country and measurement method. Self-reported sensitivity consistently runs higher than physician-diagnosed rates in every country studied — the true functional burden is larger than diagnosed figures show.
Prevalence research on MCS spans more than three decades across 15+ countries. Figures vary based on whether researchers asked about diagnosed MCS, self-reported chemical sensitivity, or functional impairment. The table below reports what each study actually measured so the numbers can be interpreted correctly.
| Country | Study / Year | Population | Prevalence | Measurement Basis |
|---|---|---|---|---|
| United States | Kreutzer et al., 1999 | California, general pop. (n=4,046) | 15.9% | Self-reported chemical sensitivity |
| United States | Kreutzer et al., 1999 | Same sample | 6.3% | Physician-diagnosed MCS |
| United States (national) | Caress & Steinemann, 2004 | US adults, national random sample | 11.2% | Self-reported chemical hypersensitivity |
| United States (national) | Caress & Steinemann, 2004 | Same sample | 2.5% | Physician-diagnosed MCS |
| United States (national) | Caress & Steinemann, 2009 | US adults, 2005–06 survey | 11.6% | Self-reported chemical hypersensitivity |
| United States (national) | Steinemann, 2018 | US adults, 2016 survey | 25.9% | Self-reported chemical sensitivity |
| United States (national) | Steinemann, 2018 | Same sample | 12.8% | Medically diagnosed MCS (self-report) |
| Australia | Steinemann, 2018 | National adult sample | 6.5% | Self-reported physician diagnosis |
| Sweden | Palmquist et al., 2014 | Population-based sample | 3.1% | IEI — functional chemical sensitivity |
| Germany | Hausteiner et al., 2005 | General population, representative survey | 9.0% | Self-reported chemical sensitivity |
| Germany | Hausteiner et al., 2005 | Same sample | 0.5% | Physician-diagnosed MCS |
| Japan | Azuma et al., 2015 | National general population | 7.5% | Chemical intolerance (questionnaire criteria) |
Why the numbers vary: Every figure above reflects a different measurement decision — who was sampled, what question was asked, and whether a physician diagnosis or self-report was required. Studies using chemical-use questions (perfumes, pesticides, cleaning products) consistently find higher rates than those requiring a formal diagnosis. The functional population living with chemical intolerance is likely larger than any single diagnosed-prevalence estimate captures.
Every study in this collection is peer-reviewed and published in an indexed scientific journal.
Studies were selected to represent the breadth of rigorous research on chemical exposure, MCS, indoor air quality, and related conditions. The collection spans 30+ years of literature from more than 15 countries.
Studies were excluded when they contained material methodological limitations that undermined their conclusions—for example, excluding the objectively strongest biological evidence (capsaicin challenge studies) while claiming to review MCS provocation research. The goal is an honest, rigorous collection, not a comprehensive bibliography.
Each card summarizes the key finding and links directly to the original source via DOI. Use the filter buttons to explore a specific area of research. Links open the abstract or full text on the publisher's site or PubMed. This collection is provided for educational purposes and is updated as new research warrants.
No. The AMA has issued nothing on MCS this century; its cited documents are from 1992 and 2000 and address clinical ecol…
MCS is a chronic, physiological condition in which everyday low-level chemical exposures produce real reactions. The def…
Why is MCS so confusing? Different triggers, thresholds, and reactions per person; hills and valleys; and why "this cure…
The by-system symptom list for MCS: neurological, respiratory, fatigue, gastrointestinal, cardiovascular and sensory. Ho…
How does MCS work in the body? Five mechanisms are under study and they are not equal: sensitized TRPV1/TRPA1 receptors …
Learn about TILT — Toxicant-Induced Loss of Tolerance — the two-stage mechanism behind Multiple Chemical Sensitivity…
EHS symptoms are real and overlap heavily with MCS. Whether electromagnetic fields cause them is not established; blinde…
Fibromyalgia and MCS overlap in some samples and both involve altered sensory processing. Not the same disease; a shared…
EDS is genetic; chemicals do not cause it. But EDS and mast cell activation syndrome often co-occur, and MCAS is a docum…
MCS and ME/CFS overlap in fatigue, cognition, sensory intolerance and autonomic symptoms. Real overlap, not one disease;…
Some people with MCS find sound, light or touch overwhelming. Sound tolerance has been measured in MCS; light and touch …
Detox, mast cells, mold, genes, the vagus nerve: each common explanation for MCS, with what is true in it, what has not …
Chronic metal exposure can look like MCS symptom for symptom. Measure metal burden with standard tests when warranted; c…
Free TILT Self-Assessment including the BREESI screener and QEESI — the gold standard for identifying chemical intoler…
Damp buildings harm respiratory health on established evidence. The CIRS biotoxin model is one group’s proposal, not i…
The CIRS model of mold biotoxins — HLA-DR variants, recirculation, low MSH, MARCoNS — stated as its originating grou…
CDC found 449 invasive mold disease cases with 45% 90-day mortality. Serious, but not evidence that household mold or MC…
The current state of MCS research: what the 2023 Molot review changed, TRP modulation, biotoxin elimination, neuroplasti…
Is MCS psychological or physical? The measurements point physical: receptor studies, skin biopsy, imaging, genetics, and…
The documented history of MCS: from Theron Randolph's 1950s observations through the 1999 consensus criteria, WHO recogn…